
Supporting Information

Article

Discovery of Active Ingredients Targeted TREM2 by SPR Biosensor-UPLC/MS Recognition System, and Investigating the Mechanism of Anti-neuroinflammatory Activity on the Lignin-amides from *Datura metel* Seeds

Si-Yi Wang [†], Yan Liu [†], Xiao-Mao Li, Adnan Mohammed Algradi, Hai Jiang, Yan-Ping Sun, Wei Guan, Juan Pan, Hai-Xue Kuang* and Bing-You Yang*

Key Laboratory of Chinese Materia, Heilongjiang University of Chinese Medicine, Ministry of Education, Harbin 150040, China; WSY06182021@163.com (S.Y.W.); lifeliuyan@163.com (Y.L.); 18216074841@163.com (X.M.L), dradnan86@hotmail.com (A.M.A); JiangHai_777@126.com (H.J.); 18704608056@163.com (Y.P.S.); myguanwei1234@yeah.net (W.G.); panjuan1002@hotmail.com (J.P)

* Correspondence: yangbingyou@hljucm.net (B.Y.Y.); hxkuang@yahoo.com (H.X.K.)

Contents:

Figure S1. Mass spectrum of standard substance for peak 1 from the TREM2-binding

Figure S2. Mass spectrum of standard substance for peak 3 from the TREM2-binding

Figure S3. Mass spectrum of standard substance for peak 4 from the TREM2-binding

Figure S4. Mass spectrum of peak 1 from the LDS

Figure S5. Mass spectrum of peak 2 from the LDS

Figure S6. Mass spectrum of peak 3 from the LDS

Figure S7. Mass spectrum of peak 4 from the LDS

Figure S8. Mass spectrum of peak 5 from the LDS

Figure S9. Mass spectrum of peak 6 from the LDS

Figure S10. Mass spectrum of peak 7 from the LDS

Figure S11. Mass spectrum of peak 8 from the LDS

Figure S12. Mass spectrum of peak 9 from the LDS

Figure S13. Mass spectrum of peak 10 from the LDS

Figure S14. Mass spectrum of peak 11 from the LDS

Figure S15. Mass spectrum of peak 12 from the LDS

Figure S31. Kruskal-Wallis analysis results for each group

Table S2. The results for Dap12 of Kruskal-Wallis

Table S4. The results for COX-2 of Kruskal-Wallis

Table S6. The results for MyD88 of Kruskal-Wallis

Table S8. The results for Caspase-1 of Kruskal-Wallis

Figure S16. Mass spectrum of peak 13 from the LDS

Figure S17. Mass spectrum of peak 14 from the LDS

Figure S18. Mass spectrum of peak 15 from the LDS

Figure S19. Mass spectrum of peak 16 from the LDS

Figure S20. Mass spectrum of peak 17 from the LDS

Figure S21. Mass spectrum of peak 18 from the LDS

Figure S22. Mass spectrum of peak 19 from the LDS

Figure S23. Mass spectrum of peak 20 from the LDS

Figure S24. Mass spectrum of peak 21 from the LDS

Figure S25. Mass spectrum of peak 22 from the LDS

Figure S26. Mass spectrum of peak 23 from the LDS

Figure S27. Mass spectrum of peak 24 from the LDS

Figure S28. Mass spectrum of peak 25 from the LDS

Figure S29. Mass spectrum of peak 26 from the LDS

Figure S30. Mass spectrum of peak 27 from the LDS

Table S1. The results for TREM2 of Kruskal-Wallis

Table S3. The results for iNOS of Kruskal-Wallis

Table S5. The results for TLR4 of Kruskal-Wallis

Table S7. The results for NLRP3 of Kruskal-Wallis

Table S9. The results for IBA-1 of Kruskal-Wallis

Citation: Wang, S.-Y.; Liu, Y.; Li, X.-M.; Algradi, A.M.; Jiang, H.; Sun, Y.-p.; Guan, W.; Pan, J.; Kuang, H.-X.; Yang, B.-Y.; et al. Discovery of active ingredients targeted TREM2 by SPR biosensor-UPLC/MS recognition system, and investigating the mechanism of anti-neuroinflammatory activity on the lignin-amides from *Datura metel* seeds. 2021, 24, x.
<https://doi.org/10.3390/xxxxx>

Academic editor: Paola Barraja

Received: 1 September 2021

Accepted: 27 September 2021

Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

Table S10. The results for p-Tau/Tau of Kruskal-Wallis

Figure S1. Mass spectrum of standard substance for peak 1 from the TREM2-binding




Figure S2. Mass spectrum of standard substance for peak 3 from the TREM2-binding




Figure S3. Mass spectrum of standard substance for peak 4 from the TREM2-binding




Figure S4. Mass spectrums of peak 1 from the LDS




Figure S5. Mass spectrum of peak 2 from the LDS




Figure S6. Mass spectrum of peak 3 from the LDS




Figure S7. Mass spectrum of peak 4 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 431 (12.405)




Figure S8. Mass spectrum of peak 5 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 435 (12.513)




Figure S9. Mass spectrum of peak 6 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 443 (12.749)




Figure S10. Mass spectrum of peak 7 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 444 (12.776)

1: TOF MS ES+
3.40e6




Figure S11. Mass spectrum of peak 8 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 444 (12.776)

1: TOF MS ES+
3.40e6




Figure S12. Mass spectrum of peak 9 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 455 (13.093)

1: TOF MS ES+
1.08e6




Figure S13. Mass spectrum of peak 10 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 469 (13.492)

1: TOF MS ES+
2.36e5




Figure S14. Mass spectrum of peak 11 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 483 (13.890)

1: TOF MS ES+
6.77e5




Figure S15. Mass spectrum of peak 12 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 523 (15.050)

1: TOF MS ES+
6.71e5




Figure S16. Mass spectrum of peak 13 from the LDS




Figure S17. Mass spectrum of peak 14 from the LDS




Figure S18. Mass spectrum of peak 15 from the LDS




Figure S19. Mass spectrum of peak 16 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 551 (15.847)




Figure S20. Mass spectrum of peak 17 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 573 (16.481)




Figure S21. Mass spectrum of peak 18 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 593 (17.061)




Figure S22. Mass spectrum of peak 19 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 603 (17.351)




Figure S23. Mass spectrum of peak 20 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 614 (17.668)




Figure S24. Mass spectrum of peak 21 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 621 (17.858)




Figure S25. Mass spectrum of peak 22 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 656 (18.864)




Figure S26. Mass spectrum of peak 23 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 668 (19.226)




Figure S27. Mass spectrum of peak 24 from the LDS

WSY-60 CHEN5
20210118 WSY-60 CHEN5 542 (15.603)




Figure S28. Mass spectrum of peak 25 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 771 (22.170)

1: TOF MS ES+
8.91e5




Figure S29. Mass spectrum of peak 26 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 807 (23.222)

1: TOF MS ES+
9.59e5




Figure S30. Mass spectrum of peak 27 from the LDS

WSY-60 CHEN5

20210118 WSY-60 CHEN5 832 (23.937)

1: TOF MS ES+
2.21e6





Figure S31. Kruskal-Wallis analysis results for each group



Kruskal-Wallis analysis results for each group of TREM2 (A); Kruskal-Wallis analysis results for each group of DAP12 (B); Kruskal-Wallis analysis results for each group of iNOS (C); Kruskal-Wallis analysis results for each group of COX-2 (D); Kruskal-Wallis analysis results for each group of TLR4 (E); Kruskal-Wallis analysis results for each group of MyD88 (F); Kruskal-Wallis analysis results for each group of NLRP3 (G); Kruskal-Wallis analysis results for each group of Caspase-1 (H); Kruskal-Wallis analysis results for each group of IBA-1 (I); Kruskal-Wallis analysis results for each group of pTau/Tau (J).

Table S1. The results for TREM2 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	1.10 [1.04, 1.12]	17.94	0.003
Model**	0.76 [0.75, 0.77]		
DPZ##	1.03 [0.98, 1.08]		
LDS (400 µg/mL) ##	1.06 [1.02, 1.08]		
LDS (200 µg/mL) ##	1.05 [1.04, 1.07]		
LDS (100 µg/mL) ##	0.91 [0.90, 0.95]		

Table S2. The results for Dap12 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	1.13 [1.07, 1.16]	20.12	0.001
Model **	0.84 [0.79, 0.89]		
DPZ ##	1.00 [0.96, 1.07]		
LDS (400 µg/mL) ##	1.18 [1.13, 1.25]		
LDS (200 µg/mL) ##	1.06 [0.99, 1.09]		
LDS (100 µg/mL) ##	0.86 [0.84, 0.90]		

Table S3. The results for iNOS of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	0.67 [0.64, 0.71]	20.40	0.001
Model **	1.53 [1.47, 1.71]		
DPZ ##	0.94 [0.93, 0.99]		
LDS (400 µg/mL) ##	0.84 [0.84, 0.96]		
LDS (200 µg/mL) ##	0.94 [0.93, 1.06]		
LDS (100 µg/mL) ##	1.10 [1.05, 1.17]		

Table S4. The results for COX-2 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	1.00 [0.99, 1.08]	21.32	0.002
Model **	2.70 [2.67, 2.78]		
DPZ ##	1.53 [1.47, 1.69]		
LDS (400 µg/mL) ##	1.50 [1.49, 1.51]		
LDS (200 µg/mL) #	2.03 [2.01, 2.51]		
LDS (100 µg/mL)	2.30 [2.19, 2.41]		

Table S5. The results for TLR4 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	1.00 [0.98, 1.01]	21.50	0.007
Model **	1.80 [1.79, 1.91]		
DPZ ##	1.24 [1.22, 1.90]		
LDS (400 µg/mL) ##	1.10 [1.01, 1.17]		
LDS (200 µg/mL) ##	1.24 [1.21, 1.28]		
LDS (100 µg/mL) #	1.64 [1.68, 1.55]		

Table S6. The results for MyD88 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	0.61 [0.57, 0.65]	20.87	0.002
Model *	1.44 [1.41, 1.45]		
DPZ #	0.93 [0.86, 0.97]		
LDS (400 µg/mL) ##	1.02 [1.00, 1.09]		
LDS (200 µg/mL) #	1.01 [0.98, 1.04]		
LDS (100 µg/mL)	1.10 [1.04, 1.12]		

Table S7. The results for NLRP3 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	0.99 [0.96, 1.03]	21.93	0.001
Model **	2.61 [2.53, 2.80]		
DPZ ##	1.48 [1.43, 1.53]		
LDS (400 µg/mL) ##	1.42 [1.38, 1.52]		
LDS (200 µg/mL) ##	1.81 [1.78, 1.90]		
LDS (100 µg/mL) #	2.10 [1.04, 2.28]		

Table S8. The results for Caspase-1 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	1.03 [0.97, 1.08]	20.83	0.003
Model **	2.43 [2.21, 2.58]		
DPZ ##	1.29 [1.26, 1.50]		
LDS (400 µg/mL) ##	1.22 [1.18, 1.35]		
LDS (200 µg/mL) ##	1.46 [1.43, 1.49]		
LDS (100 µg/mL) #	1.57 [1.52, 1.67]		

Table S9. The results for IBA-1 of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	1.00 [0.98, 1.07]		
Model **	2.49 [2.29, 2.63]		
DPZ ##	1.38 [1.30, 1.42]	21.70	0.001
LDS (400 µg/mL) ##	1.32 [1.29, 1.36]		
LDS (200 µg/mL) ##	1.83 [1.76, 1.88]		
LDS (100 µg/mL) #	2.05 [2.00, 2.23]		

Table S10. The results for p-Tau/Tau of Kruskal-Wallis ANOVA

Group	Median [<i>P</i> 25, <i>P</i> 75]	H	<i>P</i>
Normal	0.98 [0.95, 1.08]		
Model **	1.88 [1.81, 1.98]		
DPZ #	1.46 [1.68, 1.72]	20.96	0.001
LDS (400 µg/mL) ##	1.18 [1.05, 1.30]		
LDS (200 µg/mL) #	1.38 [1.34, 1.55]		
LDS (100 µg/mL) #	1.63 [1.60, 1.71]		

P* < 0.05, *P* < 0.01 vs. Control group; #*P* < 0.05, ##*P* < 0.01 vs. Model group.